CHA
FOLD

Carmichael Hill & Associates’s Amicus Therapeutics FOLD Stock Holding History

Carmichael Hill & Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-42
Closed – – 813
2021
Q3 		$0 Hold
42
– – ﹤0.01% 802
2021
Q2 		$0 Hold
42
– – ﹤0.01% 781
2021
Q1 		$0 Buy
+42
New +$650 ﹤0.01% 766

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Carmichael Hill & Associates's FOLD Position: Q4 2021 in Review

Carmichael Hill & Associates sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 42 shares.

Carmichael Hill & Associates first reported a position in FOLD in Q1 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2021. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

  • Carmichael Hill & Associates reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Carmichael Hill & Associates sold 42 Amicus Therapeutics shares in Q4 2021.
  • Carmichael Hill & Associates first reported a position in Amicus Therapeutics in Q1 2021 and held it in 3 quarters.
  • Carmichael Hill & Associates's Amicus Therapeutics position peaked at $0 in Q3 2021.
  • 224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Carmichael Hill & Associates's 13F filing for Q4 2021, filed 31 Jan 2022.